FCGR2B and systemic lupus erythematosus: Here, we highlight the possible implications of targeting ETs, especially METS, through the Syk-p38MAPK-dependent pathway in FcγRIIb−/− lupus mice that might develop novel therapeutic strategies against active lupus.